000			01830 a2200553 4500
005			20250515190126.0
264		0	_c20100722
008			201007s 0 0 eng d
022			_a1365-2893
024	7		_a10.1111/j.1365-2893.2009.01183.x _2doi
040			_aNLM _beng _cNLM
100	1		_aLukasiewicz, E
245	0	0	_aPrediction of nonSVR to therapy with pegylated interferon-alpha2a and ribavirin in chronic hepatitis C genotype 1 patients after 4, 8 and 12 weeks of treatment. _h[electronic resource]
260			_bJournal of viral hepatitis _cMay 2010
300			_a345-51 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAge Factors
650	0	4	_aAntiviral Agents _xtherapeutic use
650	0	4	_aBody Mass Index
650	0	4	_aFemale
650	0	4	_aGenotype
650	0	4	_aHepacivirus _xclassification
650	0	4	_aHepatitis C, Chronic _xdrug therapy
650	0	4	_aHumans
650	0	4	_aInterferon alpha-2
650	0	4	_aInterferon-alpha _xtherapeutic use
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aModels, Statistical
650	0	4	_aPolyethylene Glycols _xtherapeutic use
650	0	4	_aPrognosis
650	0	4	_aRNA, Viral _xblood
650	0	4	_aRecombinant Proteins
650	0	4	_aRibavirin _xtherapeutic use
650	0	4	_aSex Factors
650	0	4	_aTime Factors
650	0	4	_aTreatment Failure
650	0	4	_aViral Load
700	1		_aGorfine, M
700	1		_aFreedman, L S
700	1		_aPawlotsky, J-M
700	1		_aSchalm, S W
700	1		_aFerrari, C
700	1		_aZeuzem, S
700	1		_aNeumann, A U
773	0		_tJournal of viral hepatitis _gvol. 17 _gno. 5 _gp. 345-51
856	4	0	_uhttps://doi.org/10.1111/j.1365-2893.2009.01183.x _zAvailable from publisher's website
999			_c19177552 _d19177552